A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
| Autor: | Malin Lundkvist, Charlotte Dahle, Anna Fogdell-Hahn, Jan Hillert, Jan Lycke, Petra Nilsson, Fredrik Piehl, Tomas Olsson, Nils Feltelius, Anders Svenningsson, Elin Karlberg, Carolina Holmén |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Postmarketing surveillance Neuropsychological Tests Antibodies Monoclonal Humanized Severity of Illness Index Disability Evaluation Young Adult Multiple Sclerosis Relapsing-Remitting Natalizumab Internal medicine Severity of illness Product Surveillance Postmarketing medicine Humans Immunologic Factors Registries Adverse effect Aged Sweden Analysis of Variance Expanded Disability Status Scale business.industry Progressive multifocal leukoencephalopathy Multiple sclerosis Leukoencephalopathy Progressive Multifocal Antibodies Monoclonal Middle Aged Multiple Sclerosis Chronic Progressive medicine.disease Surgery Clinical trial Treatment Outcome Neurology Female Neurology (clinical) business medicine.drug |
| Zdroj: | Multiple Sclerosis Journal. 17:708-719 |
| ISSN: | 1477-0970 1352-4585 |
| DOI: | 10.1177/1352458510394701 |
| Popis: | Background: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010. Methods: Patients were registered in the web-based Swedish MS-registry at 40 locations and evaluated every 6 months. Adverse events and clinical outcomes were recorded. Results: One thousand one hundred and fifty-two patients were included (71.4% female) and 149 patients stopped treatment; the main reason was planned pregnancy. Anti-natalizumab antibodies were found in 4.5% (52 patients) of which 1.6% displayed persistent antibodies. Serious adverse events were rare, but included three cases with progressive multifocal leukoencephalopathy (PML). There were seven fatal cases, probably unrelated to the natalizumab treatment. For relapsing–remitting MS patients ( n = 901), mean Expanded Disability Status Scale (EDSS, −10.7%), Multiple Sclerosis Severity Scale (MSSS, −20.4%), Multiple Sclerosis Impact Scale (MSIS-29, physical −9.9%, psychological −13.3%) and Symbol Digit Modalities Test (SDMT, +10.7%) all showed significant improvements during 24 months of treatment with natalizumab. The Swedish web-based MS quality registry proved to function as a platform for post-marketing MS drug surveillance, providing long-term data regarding drug effects and adverse events beyond clinical trials. Conclusions: Our results indicate that natalizumab is generally well tolerated and has sustained efficacy for patients with active MS, though the risk of PML is still an important concern. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|